Page 287 - Haematologica Vol. 109 - July 2024

LETTER TO THE EDITOR
1La Maddalena Department of Oncology, Oncohematology and Bone Marrow Transplantation Unit, Palemo, Italy; 2Tumor Immunology Unit, Department of Health Sciences, University of Palermo School of Medicine, Istituto di Patologia Generale, Palermo, Italy; 3Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy; 4Universitè Paris Citè, Paris, France; 5AP-HP, Hôpital Saint-Louis, Hemato-oncologie, Paris, France; 6CHU de Bordeaux - Hôpital Haut Lèvêque and Centre François Magendie, Service d’Hématologie Clinique et Thérapie Cellulaire, Pessac, France; 7Universitè Grenoble Alpes, Institute for Advanced Biosciences, INSERM U1209, CNRS UMR 5309, University Hospital, Molecular Biology and Hematology Departments, Grenoble, France; 8Ematologia AOU delle Marche, Ancona, Italy; 9Department of Hematology, Centre Henri Becquerel, Rouen, France; 10Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), Hematology Unit, University of Palermo, Palermo, Italy; 11Fondazione Italiana Linfomi ETS, Modena, Italy; 12Azienda Unità Sanitaria Locale-IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; 13Hematology, Ospedale di Circolo e Fondazione Macchi - ASST Sette Laghi, Varese, Italy; 14Nantes University Hospital and CRC2 NA, Nantes, France; 15UO Ematologia AO Bianchi-Melacrino-Morelli, Reggio Calabria, Italy; 16Dipartimento di Medicina e Chirurgia, Università di Parma, AOU di Parma, Parma, Italy; 17Department of Hematology, Ravenna Hospital, Ravenna, Italy; 18Hematology Unit, IRCCS Regina Elena National Cancer Institute, Roma, Italy; 19Laboratoire d’Hèmatologie Biologique, Groupement Hospitalier Lyon-Sud/Hospices Civils de Lyon, Lyon, France;
20Service d’Anatomie Pathologique, Groupement Hospitalier Lyon- Sud/Hospices Civils de Lyon, Lyon, France; 21Oncohematology Unit, University of Perugia, Azienda Ospedaliera S.Maria, Terni, Italy; 22Ematologia Istituto Romagnolo Per Lo studio dei Tumori Dino Amadori, Meldola, Italy; 23Ospedale Oncologico A. Businco, Cagliari, Italy; 24U.O.C. di Oncoematologia Ospedali Riuniti Villa Sofia - Cervello, Palermo, Italy; 25CHIMOMO Department, University of Modena and Reggio Emilia, Modena, Italy; 26University of Eastern Piedmont Amedeo Avogadro, S.S. Antonio and Biagio and Cesaro Arrigo Hospital, Alessandria, Italy and 27IOSI, Oncology Institute of Southern Switzerland and Institute of Oncology Research (IOR), International Extranodal Lymphoma Study (IELSG), Bellinzona, Switzerland
Correspondence:
E. IANNITTO - emilio.iannitto@gmail.com
https://doi.org/10.3324/haematol.2023.284109
Received: November 2, 2023. Accepted: March 7, 2024. Early view: March 14, 2024.
©2024 Ferrata Storti Foundation Published under a CC BY-NC license
Disclosures
SF reports research funding from Janssen, Morphosys, Gilead and Beigene; consultancy for EusaPharma, Janssen, Sandoz and Abbvie; advisory board at EusaPharma, Janssen, Clinigen, Incyte and Italfarmaco; speakers honoraria from Janssen, EusaPharma, Servier and Gentili. ML reports institutional research funding from Roche, Celgene, Abvie, Millenium, Janssen, Sanofi, Verastem, Novartis, Morphosis, GSK, Oncopeptides, Karipharm, Onconova, Archigen, Beigene and BMS; honoraria for lectures, presentations, bureaus, travel accommodation from IQVIA, Incite, Celgene, Abbvie, Janssen and BMS. VC dislcoses honoraria from Kite, a Gilead Company, Bristol Myers Squibb, Novartis, Incyte, Kyowa Kirin, Abbvie, Ideogen and Takeda; travel fees from Pfizer, Kite, Gilead, Bristol Myers Squibb and Novartis; research funding paid to institution from Astra Zeneca, Bristol Myers Squibb, Novartis and Ideogen. BC discloses honoraria from Kite, Gilead, Bristol Myers Squibb, Novartis, Incyte, Kyowa Kirin, Abbvie, Ideogen and Takeda; travel fees from Pfizer, Kite, a Gilead Company, Bristol Myers Squibb and Novartis; research funding paid to institution from Astra Zeneca, Bristol Myers Squibb, Novartis and Ideogen. EZ received research support to institution from AstraZeneca, Beigene, Celgene/BMS, Incyte, Janssen, and Roche; discloses honoraria for medical educational events from Abbvie (advisory boards) from BeiGene, BMS, Curis, Eli/Lilly, Incyte, Ipsen, Janssen, Merck, Miltenyi Biomedicine and Roche; travel grants from BeiGene, Janssen, Gilead, and Roche. ML dislcoses consultancy, participation in advisory boards, an invitation to scientific meetings, institutional research support, and contracts with AbbVie, Acerta, Amgen, ADC Therapeutics, BeiGene, Celgene/BMS, Eusapharma, GSKI, Gentili, Gilead/Kite, Lilly, Novartis, Incyte J&J, Jazz, Regeneron, Roche and Sandoz. CT reports advisory/consultancy roles at and travel accommodations/expenses from Roche, Incyte, Novartis, Kite/Gilead, Amgen, Takeda and BMS.
Contributions
EI developed the study concept and design, analyzed and interpreted the data, and wrote the manuscript. CT, EZ and MF developed the study concept and design and interpreted the data. SF performed MRD investigations data analysis and wrote the manuscript. DD and MF performed MRD investigations and contributed to data analysis. LB, ATG, and CLTR contributed to the study design and supervised the diagnostic process. LM performed statistical analysis. All authors provided materials or patients, collected, assembled, analyzed and interpreted the data, gave the final approval of the manuscript and are accountable for all aspects of the work.
Funding
This research received an unrestricted contribution from Mundipharma.
Data-sharing statement
The data supporting this study’s findings are available from the corresponding author upon reasonable request.
Haematologica | 109 July 2024
2301